ESMO 2025: Data, Decisions, and the Future of Oncology
The ESMO Congress 2025 brought together leading clinicians, researchers, and pharmaceutical innovators to discuss the future of cancer treatment.
Over five days in Berlin, the event showcased late-stage clinical data and strategic insights, reaffirming ESMO's status as a key moment in the oncology calendar.
- Next-generation immunotherapies
- Antibody-drug conjugates (ADCs)
- AI-driven precision medicine
Advances in tumor-agnostic therapies and novel checkpoint inhibitors are improving patient outcomes, particularly in lung, breast, and gastrointestinal cancers.
No specific quotes were mentioned in the text.
Author's summary: ESMO Congress 2025 discussed the future of cancer treatment.
More News
- President Aliyev’s reconstruction strategy reshapes liberated lands into engines of growth
- The Coming Dementia Crisis—and the Cost of Doing Nothing
- Solar recycling: Driving down costs before volumes spike
- From MRI to Ozempic: breakthroughs that show why fundamental research must be protected
- DiversityWatch (October 29, 2025)
- Pastors and professionals